Advertisement

Gene therapy for Duchenne muscular dystrophy

An adeno-associated viral vector has successfully been used to deliver truncated versions of the dystrophin gene in a mouse model for DMD.

By | November 28, 2000

Duchenne muscular dystrophy (DMD) is the most common genetic muscle disorder, affecting 23,000 boys in the US each year. The disease results from a mutation in the gene that encodes dystrophin — the largest gene discovered to date. Adeno-associated viruses have proven the safest and most effective vehicles for delivering therapeutic genes into the muscle tissue but they are too small to carry a dystrophin gene. Now, the development of dystrophin 'mini-genes' might have resolved that problem.

In a study published in the 5 December issue of Proceedings of the National Academy of Sciences, Dr Xiao Xiao and colleagues from the University of Pittsburgh created miniature versions of dystrophin genes that were one-third the normal size. Adeno-associated viral 'packages' carrying truncated dystrophin genes were injected into the calf muscle of mice unable to produce the dystrophin protein. Functional dystrophin protein was expressed in about 90% of the muscle tissue treated. This expression lasted for at least one year.

The authors hope this gene therapy strategy could be used in a larger animal model, and eventually to treat patients. The team will also be collaborating with other researchers to develop better ways of delivering the DMD mini-gene systemically, as opposed to performing localised injections.

Advertisement

Popular Now

  1. Opinion: Too Many Mitochondrial Genome Papers
  2. Antibiotics and the Gut Microbiome
  3. Sex Differences in Pain Pathway
  4. The Sum of Our Parts
    Features The Sum of Our Parts

    Putting the microbiome front and center in health care, in preventive strategies, and in health-risk assessments could stem the epidemic of noncommunicable diseases.

Advertisement
The Scientist